Use access key #2 to skip to page content.
$13.47 -0.03 (-0.22%)
7/23/2008 4:00 PM

BioMimetic Therapeutics, Inc. (BMTI)

CAPS Rating:
**

The Company develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating BMTI

Add Stock to Watchlist

What the Community Thinks

Total Members

73 Outperforms
11 Underperforms
 

All-Stars

21 Outperforms
4 Underperforms
 

Wall Street

4 Outperforms
0 Underperforms
 

Members bullish on BMTI are also bullish on:

Members bearish on BMTI are also bearish on:

Ticker Tags

Micro Cap (4824), Healthcare (13), Medical Instruments & Supplies (112), Supplies (66)
Suggest a tag

BioMimetic Therapeutics, Inc. At A Glance

Current Price: $13.47
Last Trade Time: 7/23/2008 4:00 PM
Open: $13.50
Previous Close: $13.50
Daily Range: $13.33 - $13.52
52-Week Range: $6.35 - $18.78
Volume: 88,428
Market Cap: $250.01M
P/E Ratio: 20.15
Compare Our Special Broker Offers!

Stock Trends

BMTI VS S&P 500 (SPY)

BMTI 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for BMTI.

Top Bull Pitch

Recs

2

BioMimetic Therapeutics, Inc. (BMTI)

Avatar 12bagger (99.90) Submitted: 2/23/07 1:06 PM

I like the story here: promising new technology for bone repair, including remedies for periodontal problems. A great healthcare niche in which to market to all of us millions of agers. Admittedly the profits are still out on the horizon, but the future looks very bright.

Replies: 1 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 17 :   1 2 3 4 Next »

Recs

0

 (BMTI)

Avatar JonAtkins57 (26.74) Submitted: 5/27/08 3:38 PM : Outperform Start Price: $11.41 BMTI Score: 25.76

Market Cap: 100M - 1B
Dividend Yield (%): < 1
Net Profit Margin (%): >= 20
Gross Margin (%) >= 20
Current Ratio: >= 1
Last Price > 10 and < 12
EPS > 0

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BMTI)

Avatar tiobueno (52.86) Submitted: 4/04/08 12:40 PM : Outperform Start Price: $9.70 BMTI Score: 45.64

April 1, 2008 11:00 AM EDT

BioMimetic Therapeutics Inc. (Nasdaq: BMTI) sees some concentrated insider buying:

CFO, Lawrence E. Bullock, bought 10,000 shares on 03/28
Officer, Earl Martin Douglas, bught 1,000 shares on 03/28
Director, Gary E Friedlender, bought 8,500 shares on 03/28
Director, James Murphy, bought 5,000 shares on 03/28
CEO, Samual E. Lynch, bought 5,400 shares on 03/28.

BioMimetic fell 56% last Thursday related to an FDA safety review of Regranex, a Johnson & Johnson product, which contains the same drug product (becaplermin) as BioMimetic's product candidates. [LJ]

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BMTI)

Avatar TheTazzBot (< 20) Submitted: 4/03/08 8:03 PM : Outperform Start Price: $9.51 BMTI Score: 48.59

Expect this stock to climb back to its peak, or 80% of its peak in a few weeks

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BMTI)

Avatar sigmanu00 (< 20) Submitted: 4/03/08 10:12 AM : Outperform Start Price: $8.76 BMTI Score: 59.84

BMTI continues to grow and has extensive private investors to assist it in the provisions of cutting edge pharmaceuticals.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BMTI)

Avatar GerMax25 (39.63) Submitted: 4/01/08 11:17 AM : Outperform Start Price: $14.62 BMTI Score: -2.91

Company unfairly bore the brunt of a minor, and arguably inapplicable minor FDA warning. At the current levels, it presents a rare opportunity to buy at a dirt cheap pps. I am looking for the stock to bounce back to the mid teens in the short term.
The company has a couple of great products in trials, with early trials showing great results. Should be a multi-bagger in a couple of years.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 17 :   1 2 3 4 Next »

Wall Street

Results 1 - 4 of 4  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackStanfordRes 70.61 10/09/07 10/09/07 Outperform NS $13.49-0.15%-17.60%+17.45
TrackWachovia 80.07 08/28/07 08/28/07 Outperform NS $14.84-9.23%-12.28%+3.05
TrackCanaccord 88.88 06/01/07 06/01/07 Outperform NS $18.25-26.19%-16.61%-9.58
TrackDeutscheSec 89.63 11/08/06 11/08/06 Outperform NS $14.56-7.49%-6.93%-0.55

Results 1 - 4 of 4  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners